Yoshida, T, et al. - A randomized, open-label, controlled trial was designed to investigate whether monthly oral minodronate or semiannual subcutaneous injection of denosumab improves bone mineral density (BMD) in Asian men with prostate cancer (PCa) receiving ADT. A total of 147 individuals were recruited. Individuals were assigned randomly (1:1:1) to minodronate, denosumab, or no agent control groups. At 12 months, denosumab improved BMD at the femoral neck and total hip, whereas minodronate only increased BMD at the total hip compared with controls. In comparison with the control group, the percentage change in bone turnover markers at 12 months was significantly lower in the minodronate and denosumab groups. In Asian individuals with PCa, minodronate or denosumab can be applied for preventing bone loss related to ADT.